TCA
MRVI icon

Transcend Capital Advisors’s Maravai LifeSciences MRVI Stock Holding History

Transcend Capital Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,300
Closed -$342K – 508
2021
Q3 		$342K Buy
+8,300
New +$405K 0.03% 352

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Transcend Capital Advisors's MRVI Position: Q4 2021 in Review

Transcend Capital Advisors sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 8,300 shares — an estimated $342K sold.

Transcend Capital Advisors first reported a position in MRVI in Q3 2021 and held it in 1 quarter. The position peaked at $342K in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

  • Transcend Capital Advisors reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
  • Transcend Capital Advisors sold 8,300 Maravai LifeSciences shares in Q4 2021, an estimated $342K.
  • Transcend Capital Advisors first reported a position in Maravai LifeSciences in Q3 2021 and held it in 1 quarter.
  • Transcend Capital Advisors's Maravai LifeSciences position peaked at $342K in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Transcend Capital Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.